Mannatech, Incorporated (NASDAQ:MTEX – Get Free Report) Director Larry Jobe acquired 2,803 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $4.12 per share, for a total transaction of $11,548.36. Following the completion of the acquisition, the director directly owned 70,000 shares of the company’s stock, valued at $288,400. The trade was a 4.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Mannatech Price Performance
Shares of MTEX opened at $4.37 on Friday. The company has a market cap of $8.43 million, a price-to-earnings ratio of -0.65 and a beta of 0.61. Mannatech, Incorporated has a 1-year low of $3.80 and a 1-year high of $12.45. The company’s fifty day simple moving average is $5.48 and its 200 day simple moving average is $7.22. The company has a current ratio of 1.09, a quick ratio of 0.59 and a debt-to-equity ratio of 0.48.
Mannatech (NASDAQ:MTEX – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported $0.49 earnings per share for the quarter. Mannatech had a negative net margin of 11.97% and a negative return on equity of 2,383.34%. The business had revenue of $24.92 million for the quarter.
Mannatech Company Profile
Mannatech, Inc is a global health and wellness company that develops and markets a range of dietary supplements and personal care products through a direct selling business model. The company’s core focus is on glyconutrients, specialized carbohydrates believed to support cellular communication, which form the basis of many of its flagship offerings. Operating under a network marketing structure, Mannatech empowers independent associates to promote and distribute its products in markets around the world.
The company’s product portfolio includes nutritional supplements aimed at immune support, digestive health, and healthy aging, as well as skincare items designed to promote hydration and skin vitality.
Read More
- Five stocks we like better than Mannatech
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.
